

Medical Policy

Preimplantation Genetic Testing

Policy Number: 044

	Commercial* and Connector/ Qualified Health Plans	MassHealth	Medicare Advantage
Authorization required	X		X
No notification or authorization			
Not covered		X	

* Not all commercial plans cover this service, please check plan's benefit package to verify coverage.

Overview

The purpose of this document is to describe the guidelines Mass General Brigham Health Plan utilizes to determine medical necessity for preimplantation genetic testing (PGT) which includes preimplantation genetic diagnosis for single gene defects (PGT-M) and translocations (PGT-SR), and preimplantation genetic screening for aneuploidy (PGT-A).

Coverage Guidelines

Mass General Brigham Health Plan covers medically necessary preimplantation genetic diagnosis (PGT-M) (and associated assisted reproductive services, e.g., IVF, ICSI) for a debilitating, genetically defined and genetically predictable disease with early onset mortality or morbidity when there is no known treatment for the condition, or the available interventions are either inadequately effective or significantly burdensome. Mass General Brigham Health Plan does not cover PGT-A.

This process requires two authorizations, the first from Mass General Brigham Health Plan utilization management (UM). If approval is obtained, a second authorization must be obtained by EviCore.

The specialist and/or the primary care provider are responsible for providing all necessary clinical information including medical history of patient and partner or child, where appropriate. It is expected that the member/couple are counselled regarding the testing alternatives to PGT-M (e.g., amniocentesis, chorionic villous sampling), potential risks of PGT-M (embryo arrest, diagnostic uncertainty and unknown long-term effects of PGT-M), and that traditional prenatal diagnostic testing may still be recommended after successful PGT-M and pregnancy.

Authorization of PGT-M or PGT-SR is limited to the following criteria:

Preimplantation Genetic Testing (PGT)

1. Mass General Brigham Health Plan covers medically necessary PGT-SR to test for unbalanced chromosome rearrangements when one of the genetic parents is known to have an unbalanced translocation, a balanced reciprocal or Robertsonian translocation, or a microdeletion/duplication or other structural chromosomal abnormality associated with the birth of an affected child. Mass General Brigham Health Plan may require laboratory documentation of the genetic tests.
2. Mass General Brigham Health Plan covers medically necessary PGT-M to detect evidence of any of the following genetic disorders in an embryo when:
 - a. Both genetic parents are known carriers of a single gene autosomal recessive disorder, or one of the genetic parents is a known carrier and they have a child who has been diagnosed with the disorder such as, but **not limited to** the following:

- i. Canavan disease
 - ii. Cystic Fibrosis
 - iii. Epidermolysis Bullosa Simplex (autosomal recessive type)
 - iv. Familial dysautonomia
 - v. Fanconi's Anemia
 - vi. Gaucher Disease
 - vii. Hurler Syndrome
 - viii. Methylmalonic acidemia
 - ix. Propionic academia
 - x. Sickle Cell Anemia
 - xi. Spinal Muscular Atrophy Type I
 - xii. Spinocerebellar Ataxia (autosomal recessive type)
 - xiii. Tay-Sachs Disease
 - xiv. Thalassemia Syndromes
- b. One genetic parent is a known carrier of a single gene autosomal dominant disorder such as, but **not limited to**, the following:
- i. Epidermolysis Bullosa (autosomal dominant type)
 - ii. Huntington's Disease
 - iii. Myotonic Dystrophy
 - iv. Neurofibromatosis Type I AND II
 - v. Retinoblastoma
 - vi. Spinocerebellar Ataxia (autosomal dominant type)
 - vii. Tuberous sclerosis
- c. The genetic female parent is a known carrier of a single gene X-linked recessive disorder such as, but **not limited to** the following:
- i. Adrenoleukodystrophy
 - ii. Alport Syndrome
 - iii. Becker muscular dystrophy
 - iv. Fabry disease
 - v. Choroideremia
 - vi. Duchenne muscular dystrophy
 - vii. Fragile X syndrome
 - viii. Hemophilia A & B
 - ix. Hunter Syndrome
 - x. Incontinentia pigmenti
 - xi. Lesch-Nyhan Syndrome
 - xii. X-linked intellectual disability
3. Members with ovaries at least 40 years of age must demonstrate adequate ovarian reserve evidenced by menstrual history and results from any of the following:
- a. Clomiphene Citrate Challenge Test (CCCT) within the past 6 months by showing a Day 3 FSH level < 15 mIU/ml, Day 3 Estradiol Level < 80 pg/mL, and Day 10 FSH level < 15 mIU/ml; or
 - b. A CCCT within the parameters above performed within the past 12 months, and a Day 3 FSH level < 15 mIU/ml and Day 3 Estradiol Level < 80 pg/mL performed within the past 6 months; or
 - c. AMH level > 1.0 mg/mL or antral follicle count > 6 within the past 12 months, and Day 3 FSH <15 mIU/mL within the past 6 months.



Exclusions

1. PGT as an adjunct to infertility services for members who do not meet the *Preimplantation Genetic Testing* clinical coverage criteria above.
2. PGT is not covered for members who are not expected to be fertile due to:
 - a. age-related decline in fertility (including members with uterus/ovaries ≥ 44 years of age, and members with uterus/ovaries who have had FSH ≥ 15 mIU/ml at any time after their 40th birthday)
 - b. voluntary sterilization procedures unless the procedure has been reversed and criteria are met under “Individuals with a Sterilization Reversal” in the policy “Assisted Reproductive Services.”
3. PGT for:
 - a. Screening for aneuploidy (PGT-A) including in the setting of recurrent miscarriage, repeated failed implantation during IVF, or advanced maternal age.
 - b. Carrier testing to determine embryo’s carrier status.
 - c. Human Leukocyte antigen (HLA) typing of an embryo to identify a future suitable stem cell, tissue, or organ transplantation donor.
 - d. Translocations which will always produce an abnormal gamete such as 45XX (21;21) & 45XY(21;21).
 - e. Gender selection in the absence of a documented X-linked disorder.
 - f. Selecting non-medical traits.
 - g. Selecting against predisposition to disease when there is no single known genetic or chromosomal defect that definitively causes the disease.
 - h. Late onset/adult-onset disorders that are not listed in criteria above.
 - i. Genetic conditions contributed to by donor egg and sperm.

MassHealth Variation

Mass General Brigham Health Plan uses guidance from MassHealth for coverage determinations for its MassHealth ACO members. **As of Mass General Brigham Health Plan’s most recent policy review MassHealth does not cover preimplantation genetic testing.**

Medicare Variation

Mass General Brigham Health Plan uses guidance from the Centers for Medicare and Medicaid Services (CMS) for coverage determinations for its Medicare Advantage plan members. National Coverage Determinations (NCDs), Local Coverage Determinations (LCDs), Local Coverage Articles (LCAs) and documentation included in the Medicare manuals are the basis for coverage determinations. When there is no guidance from CMS for the requested service, Mass General Brigham Health Plan’s medical policies are used for coverage determinations. **At the time of Mass General Brigham Health Plan’s most recent policy review, CMS had no NCDs/LCDs for preimplantation genetic testing.**

Definitions

Autosomal Dominant: Autosomal dominant is one of several ways that a trait or disorder can be passed down through families. If a disease is autosomal dominant, it means you only need to get the abnormal gene from one parent in order for you to inherit the disease. One of the parents may often have the disease.

Autosomal Recessive: A disorder characterized by two mutated copies of the gene must be present in each cell in order for the disease or trait to develop. Affected persons usually have two unaffected parents who each carry a single copy of the mutated gene and they are known as carriers.

Preimplantation Genetic Testing: A test involving an embryo that has been created using assisted reproductive technology such as in-vitro fertilization. After the eggs are removed the eggs are fertilized. Those eggs which are successfully fertilized are developed into blastocyst. Five to ten cells are removed from the growing blastocyst in order to test for the specific genetic condition in question.



X-linked Dominant Disorders: Caused by mutations in the gene on the X chromosome. Females are more frequently affected than males and the chances of passing on an X linked dominant disorder differ between men and women.

X-Linked Recessive: Are caused by mutations in the genes on the X chromosome. Males are more frequently affected than females and the chances of passing on the disorder differ between men and women. Families with an X linked recessive disorder often have affected males but rarely affected females in each generation. A characteristic of X linked inheritance is that fathers cannot pass X-linked traits to their sons.

Codes

The following codes are included below for informational purposes only; inclusion of a code does not constitute or imply coverage.

This list of codes applies to commercial plans only.

Authorized CPT/HCPCS Codes	Code Description
89290	Biopsy, oocyte polar body or embryo blastomere, micro technique (for pre-implantation genetic diagnosis); less than or equal to 5 embryos
89291	Biopsy, oocyte polar body or embryo blastomere, micro technique (for pre-implantation genetic diagnosis); greater than 5 embryos

Related Policies

- [Assisted Reproductive Services/Infertility Services](#)

Effective

May 2025: Annual update. Added MassHealth variation. Clarified Medicare variation. Added one biological parent having an unbalanced translocation to conditions eligible for PGT-SR. Added Retinoblastoma to list of single gene autosomal dominant disorders. References updated.

March 2024: Annual update.

March 2023: Annual update. Medicare Advantage added to table. Subheading title changed to Preimplantation Genetic Testing (PGT). Exclusions updated. Medicare Advantage language added. Definitions updated.

March 2022: Annual update. References updated.

March 2021: Annual update. References updated.

June 2020: Annual update. Under coverage guidelines added clarification statement regarding authorization requirements. Updated references.

March 2019: Annual update. Updated references.

August 2018: Ad hoc update. Added language under item 1 subheading Preimplantation Genetic Diagnosis to include *(and associated assisted reproductive services; e.g. IVF, ICSI)*.

April 2018: Annual update.

July 2017: Annual update. Added the exclusion “PGD Services if the member or member’s spouse are using illicit substances or abusing substances known to negatively interfere with fertility or fetal development (e.g., marijuana, opiates, cocaine, or alcohol)”

July 2016: Annual update.

July 2015: Annual update. Updated references

August 2014: Annual update. Added language to Coverage Guidelines, “a debilitating genetic disease with early onset mortality or morbidity and when there is no known treatment for the condition, or the available interventions are either inadequately effective or significantly burdensome.” Added exclusions: 3f selecting for non-medical traits and 3j Genetic conditions contributed to by donor egg and sperm.



June 2013: Annual update. Added specific genetic disorders.

June 2012: Effective date.

References

American College of Obstetricians and Gynecologists. Preimplantation Genetic Testing: ACOG Committee Opinion Summary, Number 799. *Obstet Gynecol*. Mar 2020; 135(3): 752-753. PMID 32080047

American College of Obstetricians and Gynecologists. Preimplantation genetic screening for aneuploidy. ACOG Committee Opinion No. 430. *Obstet Gynecol* 2009; 113:766-767. Reaffirmed by AGOC in 2014. Accessed 2016.

American Society for Reproductive Medicine. Preimplantation Genetic Testing, Patient Fact Sheet. Revised 2014. Available at asrm.org. Accessed December 20, 2017.

Anver Kuliev & Svetlana Rechitsky. Preimplantation genetic testing: current challenges and future prospects, *Expert Review of Molecular Diagnostics* 2017 17:12, 1071-1088, DOI: [10.1080/14737159.2017.1394186](https://doi.org/10.1080/14737159.2017.1394186)

Bhatt SJ, Marchetto NM, Roy J, Morelli SS, McGovern PG. Pregnancy outcomes following in vitro fertilization frozen embryo transfer (IVF-FET) with or without preimplantation genetic testing for aneuploidy (PGT-A) in women with recurrent pregnancy loss (RPL): a SART-CORS study. *Hum Reprod*. 2021 Jul 19;36(8):2339-2344.

Brezina PR, and Kutteh WH, Clinical Applications of Preimplantation Genetic Testing. *BMJ* 2014;349: g761.doi: 10.1136/bmj.g7611

Checa, M., Alonso-Coello, P., Sola, I., Robles, A., Carreras, R & Balasch J., IVF/ICSI with or without preimplantation genetic screening for aneuploidy in couples without genetic disorders: a systematic review and meta-analysis. *J. Assist Reprod Genet* 2009;26:273-283.

Cooper, A., Jungheim E. Preimplantation genetic testing: indications and controversies. *Clin Lab Med*. 2010; 30: 519-531.

Cornelisse S, Zagers M, Kostova E, et al. Preimplantation genetic testing for aneuploidies (abnormal number of chromosomes) in in vitro fertilisation. *Cochrane Database Syst Rev*. Sep 08 2020; 9:CD005291. PMID 32898291

Dahdouh EM, Balayla J et al., Impact of blastocyst biopsy and comprehensive chromosome screening technology on preimplantation genetic screening: a systematic review of randomized controlled trials. *Reproductive BioMedicine Online* 2015;30:281–289.

Dahdouh EM, Balayla J et al., Preimplantation genetic screening using comprehensive chromosome screening: evidence and remaining challenges. *Human Reproduction* 2015;30:1515-16.

Ethics Committee of the American Society for Reproductive Medicine. Use of preimplantation genetic diagnosis for a serious adult onset condition: a committee opinion. *Fertility and Sterility* 2013;100:54-57.

Franssen, M., Musters, A., Veen, V, et al., Reproductive outcome after PGD in couples with recurrent miscarriage carrying a structural chromosome abnormality: a systematic review. *Human Reproduction Update* 2011;17:467-475.

Franasiak JM, Forman EJ et al. The nature of aneuploidy with increasing age of the female partner: a review of 15,169 consecutive trophectoderm biopsies evaluated with comprehensive chromosomal screening. *Fertility and Sterility* 2014;101:656–63.

Genetics Committee of the Society of Obstetricians and Gynaecologists of Canada. Preimplantation Genetic Testing. *Journal d'obstetrique et gynecologie du Canada: JOGC* 2009;31:761-775.



Genetics Home Reference, a service of the National Library of Medicine accessed at: <http://ghr.nlm.nih.gov/> Accessed 2012 and 2015.

Ginsburg ES, Baker VL, et al., Use of preimplantation genetic diagnosis and preimplantation genetic screening in the United States: A Society for Assisted Reproductive Technology Writing Group paper. *Fertility and Sterility* 2011;96:865–8.

Gleicher, N., Kushnir, V., and Bard, D. Preimplantation genetic screening (PGS) still in search of a clinical application: a systematic review. *Reprod Biol Endocrinol* 2014;12:22.

Harper JC., Sengupta, SB., Preimplantation genetic diagnosis: state of the art. *Hum Genet* 2012;131:175-186.

Harton GL, Munne S, et al. Diminished effect of maternal age on implantation after preimplantation genetic diagnosis with array comparative genomic hybridization. *Fertility and Sterility* 2013;100:1695–703.

Lee E, Illingworth P et al., The clinical effectiveness of preimplantation genetic diagnosis for aneuploidy in all 24 chromosomes (PGD-A): systematic review. *Human Reproduction* 2015;30:473–483.

Lews M, Tan J, Taskin O, et al. Does preimplantation genetic diagnosis improve reproductive outcome in couples with recurrent pregnancy loss owing to structural chromosomal rearrangement? A systematic review. *Reprod Biomed Online*. 2018;36(6):677-685.

Liebaers, I., Desmyttere, S., Et Al. Report on consecutive series of 681 children born after blastomere biopsy for preimplantation genetic diagnosis. *Human Reproduction* 2010;25:275-282.

Mastenbroek S, M. Twisk et al., Preimplantation genetic screening: a systematic review and meta-analysis of RCTs. *Human Reproduction Update* 2011;17, No.4 pp. 454–466.

Mastenbroek, S., Twisk, M., Et al. In vitro fertilization with preimplantation genetic screening. *New England Journal of Medicine* 2007;357:9-17.

Munne S, Kaplan B, Frattarelli JL, et al. Preimplantation genetic testing for aneuploidy versus morphology as selection criteria for single frozen-thawed embryo transfer in good-prognosis patients: a multicenter randomized clinical trial. *Fertil Steril*. Dec 2019; 112(6): 1071-1079.e7. PMID 31551155

Natsuaki MN, Dimler LM. Pregnancy and child developmental outcomes after preimplantation genetic screening: a meta-analytic and systematic review. *World J Pediatr*. 2018 Dec;14(6):555-569.

Papas RS, Kutteh WH. Genetic Testing for Aneuploidy in Patients Who Have Had Multiple Miscarriages: A Review of Current Literature. *Appl Clin Genet*. 2021 Jul 23;14:321-329. doi: 10.2147/TACG.S320778. PMID: 34326658; PMCID: PMC8315809.

Practice Committees of the American Society for Reproductive Medicine and the Society for Assisted Reproductive Technology. Electronic address: asrm@asrm.org. The use of preimplantation genetic testing for aneuploidy: a committee opinion. *Fertil Steril*. 2024 Sep;122(3):421-434. doi: 10.1016/j.fertnstert.2024.04.013. Epub 2024 May 18. PMID: 38762806.

Practice Committee and Genetic Counseling Professional Group (GCPG) of the American Society for Reproductive Medicine. Clinical management of mosaic results from preimplantation genetic testing for aneuploidy (PGT-A) of blastocysts: a committee opinion. *Fertil Steril*. Aug 2020; 114(2): 246-254.

Rubio C, Bellver J, Rodrigo L, et al. In vitro fertilization with preimplantation genetic diagnosis for aneuploidies in advanced maternal age: a randomized, controlled study. *Fertil Steril*. 2017;107(5):1122-1129. PMID 28433371



Vaiarelli A, Cimadomo D, Capalbo A, et al. Pre-implantation genetic testing in ART: who will benefit and what is the evidence? *Journal of Assisted Reproduction and Genetics* 2016;33(10):1273–8

World Health Organization [WHO]. Genetic counseling services. Accessed Nov 12, 2019. Available at URL address: <http://www.who.int/genomics/professionals/counselling/en/>

Zegers-Hochschild F, Adamson GD, Dyer S, et al. The International Glossary on Infertility and Fertility Care, 2017. *Fertility and Sterility* 2017;108(3):393–406.

